摘要
目的:观察放疗联合化疗及瘤内注射EIB缺失腺病毒(H101)综合治疗鼻咽癌的近期疗效和不良反应。方法:符合入选标准的56例鼻咽癌患者先行化疗和同期颈部肿瘤瘤内注射H101,每天1次,每次1支(5×10^11病毒颗粒数/0.5mL),连续5天,化疗用PF方案(DDP20mg/m^2静滴,d1~d5,5-FU500mg/m^2静滴,d1~d5),21天为1疗程。连续2疗程后进行放疗。结果:56例鼻咽癌患者放疗结束时肿瘤消退率为71.4%,好转率为28.6%。放疗后3个月肿瘤消退率为100%。放疗后6个月有2例颈部肿瘤复发。不良反应为注射部位局部疼痛19.6%,非感染性发热41.7%,流感样症状8.9%,白细胞下降42.9%,恶心呕吐33.9%,口腔黏膜损害100%。结论:放疗联合化疗及基因治疗鼻咽癌有明确的近期疗效,毒副反应轻,可望成为鼻咽癌新的综合治疗模式,远期疗效有待进一步观察。
Objective: To evaluate the short-term effects and toxicities of radiotherapy combined with chemotherapy and intratumoral injection of an EIB gene-deleted adenovirus (H101) in treating patients with nasopharyngeal carcinoma. Methods: A total of 56 patients with nasopharyngeal carcinoma were recruited. They first received chemotherapy based on PF regimen(cisplatin 20 mg/m^2 ivgtt,qd×5 d;5-fluorouracil 500 mg/m^2 ivgtt, qd×5 d). Cervical intratumoral injection of H101 (5 ×10H viral particle/0.5 mL) was simultaneously administered to patients once daily for 5 consecutive days. Treatment repeated every 3 weeks as 1 cycle. Patients received radiotherapy after they completed 2 cycles of chemotherapy. Results: Among 56 patients, the complete response rate was 71.4% and partial response rate was 28.6% at the end of radiotherapy. The complete response rate was 100% at 3 months after radiotherapy. Recurrence of cervical tumors was found in 2 patients at 6 months after radiotherapy. Main side effects included injection site reaction (19.6 % ), fever independent of infection(41.7 % ), flu-like symptom (8.9 % ), leukopenia (42.9%), nausea and vomiting ( 33.9 % ), and oral cavity mucosal ulcer ( 100% ). Conclusions: The combination of radiotherapy and chemotherapy plus H101 injection possessed a distinct efficacy in patients with nasopharyngeal carcinoma with lower toxicities. It may become a new pattern of comprehensive therapy for nasopharyngeal carcinoma. The long-term effect need to be further investigated.
出处
《肿瘤》
CAS
CSCD
北大核心
2006年第5期453-455,共3页
Tumor
基金
广西壮族自治区科技攻关项目(编号:0322025-5)
关键词
鼻咽肿瘤
抗肿瘤联合化疗方案
放射疗法
基因疗法
腺病毒
人
Nasopharyngeal neoplasms
Antineoplastie combined chemotherapy protocols
Radiotherapy
Gene therapy
Adenovirus, human